Table 2.
Effect of expression levels of CDKN2B-AS1 on the clinical characteristics of patients with NPC (n=38)
| Characteristic | Case (n=38) | CDKN2B-AS1 low expression (n=7) | CDKN2B-AS1 high expression (n=31) | P |
|---|---|---|---|---|
| Gender | ||||
| Male | 21 | 5 | 16 | 0.4267 |
| Female | 17 | 2 | 15 | |
| Age (years old) | ||||
| <55 | 25 | 8 | 17 | 0.2955 |
| ≥55 | 13 | 3 | 10 | |
| TNM stage | ||||
| I-II | 18 | 6 | 12 | 0.0381 |
| III-IV | 20 | 1 | 19 | |
| EA-IgA positive | ||||
| <1:10 | 15 | 2 | 13 | 0.6807 |
| ≥1:10 | 23 | 5 | 18 | |
| VCA-IgA positive | ||||
| <1:80 | 7 | 45 | 2 | 0.0008 |
| ≥1:80 | 31 | 2 | 29 | |
| Pathological type | ||||
| Non-keratinizing | 33 | 5 | 28 | 0.2227 |
| Keratinizing | 5 | 2 | 3 | |
| Lymphatic metastasis | ||||
| No | 12 | 6 | 6 | 0.0020 |
| Yes | 26 | 1 | 25 |
Note: CDKN2B-AS1: CDKN2B antisense RNA 1; NPC: nasopharyngeal carcinoma; TNM: tumor metastasis.